http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
엄정필,임수근,허보영 慶尙大學校生産技術硏究所 1995 生産技術硏究所論文集 Vol.11 No.-
Microstructure of Mg-1 ~ 6wt%Zn, Mg-1.5wt%Mn and Mg-2wt%Zn-1.5wt%Mn alloys have been investigated by means of hardness test, optical microscopy, scanning electron microscopy and energy dispersive spectroscopy. The Mg alloy castings have been casted into the metallic mold with room temperature, and cooling part of metallic mold have located in it's lower part. The microstructure of Mg-Zn cast alloys revealed MgZn compound around the secondary dendrite arms. Analysis by scanning electron microscopy/energy dispersive spectroscopy showed that the composition of MgZn compound was Mg-77wt%Zn, which corresponds with the value of Mg-74.5wt%Zn given by Clack and Rhines. The addition of Mn in Mg-Zn alloys refined the grain size in as-casted alloys. Manganese additions also increased the vickers hardness.
손영택,엄보영 한국약제학회 1997 Journal of Pharmaceutical Investigation Vol.27 No.3
Glibenclamide is a second generation sulfonylurea that is orally active as a hypoglycemic drug. It exists as a crystalline powder which is sparingly soluble in water. It was investigated that the potential of glibenclamide to exhibit polymorphism. Three polymorphic modifications (form 1, form 2 and form 3) and three pseudopolymorphic modifications (form 4, form 5 and form 6) were obtained by crystallization from different organic solvents. The isolated crystal forms were characterized by differential scanning calorimetry(DSC), thermogravimetric analysis(TGA) and X-ray crystallography powder diffraction studies. Form 1 was the most stable and melt at 175.4℃. Form 2 was metastable and melt at 151.0℃. Form 3 was a new polymorphic modification because it was different from form 1 and form 2 in X-ray crystallography powder diffraction data. Form 4 was a 1 : 7(toluene : glibenclamide) toluene solvate : form 5 was a 1 : 5(toluene : glibenclamide) toluene solvate: form 6 was a 3:8(pentanol : glibenclamide) pentanol solvate. All forms were stable in 3-month storage under 0% or 100% humidity condition. The dissolution rate of form 4 was highest: those of form 2, form 3, form 1, form 5 and form 6 followed.
허갑범,이현철,임승길,송영득,차봉수,원영준,김선호,김경래,권석호,정보영,남수연,김태승,엄재화 대한내분비학회 1997 Endocrinology and metabolism Vol.12 No.2
Backgrounds: Pituitary hyperplasia can mimic pituitary adenoma. In MRI, enlarged pituitary gland is enhanced homogenously with upward convexity of the superior margin of the gland .The best definition of hyperplasia in the pituitary hyperplasia seems to be a multiplication of one or more cell types. But definition, etiology and clinical courses of this disease are not clear, Method : We reviewed clinical symptoms, MRI, and pathologic findindings in 6 patients with pituitary hyperplasia. Result: 1. Major clinical symptoms were headache(100%), visual field defect(84%), polyuria/polydipsia (64%), and irregular mensturation(32%). Other symptoms were amenorrhea(16%) and galactorrhea (16%). 2. Three of five cases showed abnormal responses to combined pituitary function test, 3. MRI findings were pituitary hyperplasia(4), macroadenoma(l), and microadenoma(1). 4. In two operated cases, there was no adenoma. One case showed hyperplasia of lactotroph cells, the other was hyperplasia of gonadotroph cells confirmed by the examination of immunocytochemistry. Conclusion : Pituitary hyperplasia should be considered in patients with enlarged pituitary gland without focal mass lesion. (J Kor Soc Endocrinol 12:155-164, 1997)